UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Molecular pathology of the thalassemic syndromes

Author
Edward J Benz, Jr, MD
Section Editor
Stanley L Schrier, MD
Deputy Editor
Jennifer S Tirnauer, MD

INTRODUCTION

The deficiencies in hemoglobin biosynthesis that characterize the various forms of thalassemia arise from mutations in or near the two globin gene clusters which encode the globin polypeptide subunits of hemoglobin. To date, no forms of thalassemia arising primarily from defects in iron or heme metabolism have been described. All known forms are due to inherited defects in the biosynthesis or post-translational stability of the globin subunits themselves.

Because of their small size, their arrangement into relatively compact gene clusters, and their well characterized physiology, pathology, and clinical genetics, the globin genes were the first human genes to be cloned and thoroughly characterized. The mutations that cause the thalassemia syndromes were the first to be defined at the level of their DNA structure. Indeed, the delineation of the impact of these mutations on mRNA and protein expression provided the paradigm for the identification of mutations causing other diseases.

The molecular pathology of the thalassemic syndromes will be discussed here. This subject is best understood from the perspective of the normal structure and function of the genes encoding the individual globins [1]. The first section of this review will outline the essential features of normal hemoglobin biosynthesis and its underlying molecular biology. (See "Principles of molecular genetics" and "Structure and function of normal hemoglobins".)

The second section will discuss illustrative examples of the over 100 different mutations causing thalassemia and explain their effects on globin synthesis. The pathophysiologic and clinical aspects of the thalassemic syndromes are discussed separately. (See "Pathophysiology of alpha thalassemia" and "Pathophysiology of beta thalassemia" and "Clinical manifestations and diagnosis of the thalassemias".)

CLINICAL RELEVANCE OF THE MOLECULAR BASIS OF THALASSEMIA

The globin gene clusters and their RNA and globin protein products are the most thoroughly understood in the human genome at the level of their basic structure and arrangement; regulated expression during embryonic, fetal, and adult life; structure-function relationships of the globin proteins; and physiology and pathophysiology of conditions arising from alterations in the genes or elements that control them.

                              

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Sep 28 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Steinberg MH, Benz EJ Jr. Pathobiology of the human erythrocyte and its hemoglobins. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ, Shattil SJ, et al (Eds), Churchill Livingstone, Philadelphia 2000. p.356.
  2. Horak CE, Mahajan MC, Luscombe NM, et al. GATA-1 binding sites mapped in the beta-globin locus by using mammalian chIp-chip analysis. Proc Natl Acad Sci U S A 2002; 99:2924.
  3. Yu C, Niakan KK, Matsushita M, et al. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood 2002; 100:2040.
  4. Balduini CL, Pecci A, Loffredo G, et al. Effects of the R216Q mutation of GATA-1 on erythropoiesis and megakaryocytopoiesis. Thromb Haemost 2004; 91:129.
  5. Wada T, Kubota T, Fukushima Y, Saitoh S. Molecular genetic study of japanese patients with X-linked alpha-thalassemia/mental retardation syndrome (ATR-X). Am J Med Genet 2000; 94:242.
  6. Steensma DP, Higgs DR, Fisher CA, Gibbons RJ. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood 2004; 103:2019.
  7. Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood 2005; 105:443.
  8. Haas PS, Roy NB, Gibbons RJ, et al. The role of X-inactivation in the gender bias of patients with acquired alpha-thalassaemia and myelodysplastic syndrome (ATMDS). Br J Haematol 2009; 144:538.
  9. Bank A. Understanding globin regulation in beta-thalassemia: it's as simple as alpha, beta, gamma, delta. J Clin Invest 2005; 115:1470.
  10. Chen JJ. Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to anemias. Blood 2007; 109:2693.
  11. Weiss MJ, dos Santos CO. Chaperoning erythropoiesis. Blood 2009; 113:2136.
  12. dos Santos CO, Duarte AS, Saad ST, Costa FF. Expression of alpha-hemoglobin stabilizing protein gene during human erythropoiesis. Exp Hematol 2004; 32:157.
  13. Kong Y, Zhou S, Kihm AJ, et al. Loss of alpha-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia. J Clin Invest 2004; 114:1457.
  14. Feng L, Zhou S, Gu L, et al. Structure of oxidized alpha-haemoglobin bound to AHSP reveals a protective mechanism for haem. Nature 2005; 435:697.
  15. Yu X, Kong Y, Dore LC, et al. An erythroid chaperone that facilitates folding of alpha-globin subunits for hemoglobin synthesis. J Clin Invest 2007; 117:1856.
  16. Yu X, Mollan TL, Butler A, et al. Analysis of human alpha globin gene mutations that impair binding to the alpha hemoglobin stabilizing protein. Blood 2009; 113:5961.
  17. Baudin-Creuza V, Vasseur-Godbillon C, Pato C, et al. Transfer of human alpha- to beta-hemoglobin via its chaperone protein: evidence for a new state. J Biol Chem 2004; 279:36530.
  18. Lai MI, Jiang J, Silver N, et al. Alpha-haemoglobin stabilising protein is a quantitative trait gene that modifies the phenotype of beta-thalassaemia. Br J Haematol 2006; 133:675.
  19. dos Santos CO, Zhou S, Secolin R, et al. Population analysis of the alpha hemoglobin stabilizing protein (AHSP) gene identifies sequence variants that alter expression and function. Am J Hematol 2008; 83:103.
  20. Han AP, Fleming MD, Chen JJ. Heme-regulated eIF2alpha kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia. J Clin Invest 2005; 115:1562.
  21. Khandros E, Thom CS, D'Souza J, Weiss MJ. Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemia. Blood 2012; 119:5265.
  22. Weatherall DJ, Clegg JB, Higgs DR, Wood WG. The hemoglobinopathies. In: The Metabolic and Molecular Bases of Inherited Disease, 7th ed, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 1995. p.3417.
  23. Driscoll MC, Dobkin CS, Alter BP. Gamma delta beta-thalassemia due to a de novo mutation deleting the 5' beta-globin gene activation-region hypersensitive sites. Proc Natl Acad Sci U S A 1989; 86:7470.
  24. Giordano PC, Harteveld CL, Haak HL, et al. A case of non-beta-globin gene linked beta thalassaemia in a Dutch family with two additional alpha-gene defects: the common -alpha3.7 deletion and the rare IVS1-116 (A-->G) acceptor splice site mutation. Br J Haematol 1998; 103:370.
  25. Viprakasit V, Kidd AM, Ayyub H, et al. De novo deletion within the telomeric region flanking the human alpha globin locus as a cause of alpha thalassaemia. Br J Haematol 2003; 120:867.
  26. Humphries RK, Ley T, Turner P, et al. Differences in human alpha-, beta- and delta-globin gene expression in monkey kidney cells. Cell 1982; 30:173.
  27. Ojwang PJ, Nakatsuji T, Gardiner MB, et al. Gene deletion as the molecular basis for the Kenya-G gamma-HPFH condition. Hemoglobin 1983; 7:115.
  28. Kulozik AE, Thein SL, Wainscoat JS, et al. Thalassaemia intermedia: interaction of the triple alpha-globin gene arrangement and heterozygous beta-thalassaemia. Br J Haematol 1987; 66:109.
  29. Sgourou A, Routledge S, Antoniou M, et al. Thalassaemia mutations within the 5'UTR of the human beta-globin gene disrupt transcription. Br J Haematol 2004; 124:828.
  30. Spritz RA, Jagadeeswaran P, Choudary PV, et al. Base substitution in an intervening sequence of a beta+-thalassemic human globin gene. Proc Natl Acad Sci U S A 1981; 78:2455.
  31. Orkin SH, Antonarakis SE, Loukopoulos D. Abnormal processing of beta Knossos RNA. Blood 1984; 64:311.
  32. Orkin SH, Nathan DG. The Thalassemias. In: Nathan and Oski's Hematology of Infancy and Childhood, 6th ed, Nathan DG, Orkin SH, Ginsberg D, Look AT (Eds), WB Saunders, Philadelphia 2003. p.842.
  33. Schell T, Kulozik AE, Hentze MW. Integration of splicing, transport and translation to achieve mRNA quality control by the nonsense-mediated decay pathway. Genome Biol 2002; 3:REVIEWS1006.
  34. Thein SL. Dominant beta thalassaemia: molecular basis and pathophysiology. Br J Haematol 1992; 80:273.
  35. Kazazian HH Jr, Dowling CE, Hurwitz RL, et al. Dominant thalassemia-like phenotypes associated with mutations in exon 3 of the beta-globin gene. Blood 1992; 79:3014.
  36. Hunt DM, Higgs DR, Winichagoon P, et al. Haemoglobin Constant Spring has an unstable alpha chain messenger RNA. Br J Haematol 1982; 51:405.
  37. Adams JG 3rd, Boxer LA, Baehner RL, et al. Hemoglobin Indianapolis (beta 112[G14] arginine). An unstable beta-chain variant producing the phenotype of severe beta-thalassemia. J Clin Invest 1979; 63:931.